Clinical Trials and Progress in Metastatic Colon Cancer

Kabir Mody, Tanios Bekaii-Saab

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

Original languageEnglish (US)
Pages (from-to)349-365
Number of pages17
JournalSurgical Oncology Clinics of North America
Volume27
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Colonic Neoplasms
Clinical Trials
DNA Mismatch Repair
Combination Drug Therapy
Immunotherapy
Colorectal Neoplasms
Decision Making
Technology
Mortality
Therapeutics
Neoplasms
Optimism

Keywords

  • BRAF
  • Clinical trials
  • Colorectal cancer
  • Her2
  • Immunotherapy
  • KRAS

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Clinical Trials and Progress in Metastatic Colon Cancer. / Mody, Kabir; Bekaii-Saab, Tanios.

In: Surgical Oncology Clinics of North America, Vol. 27, No. 2, 01.04.2018, p. 349-365.

Research output: Contribution to journalReview article

@article{353e45b0b8cd4b4cb4769a5bff4211de,
title = "Clinical Trials and Progress in Metastatic Colon Cancer",
abstract = "Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.",
keywords = "BRAF, Clinical trials, Colorectal cancer, Her2, Immunotherapy, KRAS",
author = "Kabir Mody and Tanios Bekaii-Saab",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.soc.2017.11.008",
language = "English (US)",
volume = "27",
pages = "349--365",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Clinical Trials and Progress in Metastatic Colon Cancer

AU - Mody, Kabir

AU - Bekaii-Saab, Tanios

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

AB - Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide but associated mortality has declined in recent decades. Genomic profiling of the disease has resulted in the definition of subsets of patients—for example, KRAS, NRAS, or BRAF mutated; Her2 amplified; and mismatch repair deficient—which has enabled personalization of therapeutic decision making. These subsets are guiding drug development and combination therapy approaches using both targeted therapies and immunotherapies. Further refinement based on molecular discoveries and the emergence of newer technologies to enable new discoveries allow for great optimism for the future on behalf of patients with colon cancer.

KW - BRAF

KW - Clinical trials

KW - Colorectal cancer

KW - Her2

KW - Immunotherapy

KW - KRAS

UR - http://www.scopus.com/inward/record.url?scp=85042790466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042790466&partnerID=8YFLogxK

U2 - 10.1016/j.soc.2017.11.008

DO - 10.1016/j.soc.2017.11.008

M3 - Review article

VL - 27

SP - 349

EP - 365

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 2

ER -